Peringatan Keamanan

Oral, rat: LD50 = 900 mg/kg; Oral, mouse: LD50 = 1000 mg/kg. Symptoms of overdose include seizures, hypotension, cardiac arrhythmias, and cardiovascular collapse.

Quinacrine

DB01103

small molecule investigational

Deskripsi

An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.

Struktur Molekul 2D

Berat 399.957
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 5 to 14 days
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Absorbed rapidly from the gastrointestinal tract following oral administration.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

413 Data
Artemether The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Artemether.
Lumefantrine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Lumefantrine.
Thiethylperazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Thiethylperazine.
Promazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Promazine.
Prochlorperazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Prochlorperazine.
Chlorpromazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Chlorpromazine.
Triflupromazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Triflupromazine.
Fluphenazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Fluphenazine.
Thioridazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Thioridazine.
Moricizine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Moricizine.
Trifluoperazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Trifluoperazine.
Perphenazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Perphenazine.
Mesoridazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Mesoridazine.
Acetophenazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Acetophenazine.
Promethazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Promethazine.
Alimemazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Alimemazine.
Methotrimeprazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Methotrimeprazine.
Periciazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Periciazine.
Acepromazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Acepromazine.
Aceprometazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Aceprometazine.
Pipotiazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Pipotiazine.
Thioproperazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Thioproperazine.
BL-1020 The risk or severity of QTc prolongation can be increased when Quinacrine is combined with BL-1020.
Cyamemazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Cyamemazine.
Methylene blue The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Methylene blue.
Propiopromazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Propiopromazine.
Perazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Perazine.
Butaperazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Butaperazine.
Chlorproethazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Chlorproethazine.
Thiazinam The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Thiazinam.
Dixyrazine The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Dixyrazine.
Perphenazine enanthate The risk or severity of QTc prolongation can be increased when Quinacrine is combined with Perphenazine enanthate.
Dapsone The risk or severity of adverse effects can be increased when Quinacrine is combined with Dapsone.
Tipiracil The excretion of Tipiracil can be decreased when combined with Quinacrine.
Vemurafenib The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Quinacrine.
Pitolisant The serum concentration of Quinacrine can be decreased when it is combined with Pitolisant.
Varenicline The excretion of Varenicline can be decreased when combined with Quinacrine.
Solriamfetol The serum concentration of Solriamfetol can be increased when it is combined with Quinacrine.
Ranitidine The serum concentration of Ranitidine can be increased when it is combined with Quinacrine.
Prazosin The serum concentration of Prazosin can be increased when it is combined with Quinacrine.
Linagliptin The metabolism of Quinacrine can be decreased when combined with Linagliptin.
Choline salicylate The serum concentration of Choline salicylate can be increased when it is combined with Quinacrine.
Choline The serum concentration of Choline can be increased when it is combined with Quinacrine.
Metformin The serum concentration of Metformin can be increased when it is combined with Quinacrine.
Norepinephrine The serum concentration of Norepinephrine can be increased when it is combined with Quinacrine.
Reserpine The serum concentration of Reserpine can be increased when it is combined with Quinacrine.
Pramipexole The serum concentration of Pramipexole can be increased when it is combined with Quinacrine.
Cimetidine The metabolism of Quinacrine can be decreased when combined with Cimetidine.
Epinephrine The serum concentration of Epinephrine can be increased when it is combined with Quinacrine.
Lamivudine The serum concentration of Lamivudine can be increased when it is combined with Quinacrine.
Amantadine The serum concentration of Amantadine can be increased when it is combined with Quinacrine.
Dopamine The serum concentration of Dopamine can be increased when it is combined with Quinacrine.
Memantine The serum concentration of Memantine can be increased when it is combined with Quinacrine.
Histamine The serum concentration of Histamine can be increased when it is combined with Quinacrine.
Agmatine The serum concentration of Agmatine can be increased when it is combined with Quinacrine.
Nafamostat The serum concentration of Nafamostat can be increased when it is combined with Quinacrine.
Metreleptin The metabolism of Quinacrine can be increased when combined with Metreleptin.
Isavuconazole The metabolism of Quinacrine can be decreased when combined with Isavuconazole.
Diltiazem The metabolism of Quinacrine can be decreased when combined with Diltiazem.
Ciprofloxacin The metabolism of Quinacrine can be decreased when combined with Ciprofloxacin.
Verapamil The metabolism of Quinacrine can be decreased when combined with Verapamil.
Erythromycin The serum concentration of Quinacrine can be increased when it is combined with Erythromycin.
Gestodene The metabolism of Quinacrine can be decreased when combined with Gestodene.
Nabiximols The metabolism of Quinacrine can be decreased when combined with Nabiximols.
Troglitazone The metabolism of Quinacrine can be decreased when combined with Troglitazone.
Chloramphenicol The metabolism of Quinacrine can be decreased when combined with Chloramphenicol.
Aprepitant The metabolism of Quinacrine can be decreased when combined with Aprepitant.
Mibefradil The metabolism of Quinacrine can be decreased when combined with Mibefradil.
Seproxetine The metabolism of Quinacrine can be decreased when combined with Seproxetine.
Medical Cannabis The metabolism of Quinacrine can be decreased when combined with Medical Cannabis.
Curcumin sulfate The metabolism of Quinacrine can be decreased when combined with Curcumin sulfate.
Fluticasone propionate The metabolism of Quinacrine can be decreased when combined with Fluticasone propionate.
Imatinib The metabolism of Quinacrine can be decreased when combined with Imatinib.
Fluticasone furoate The metabolism of Fluticasone furoate can be decreased when combined with Quinacrine.
Letermovir The metabolism of Quinacrine can be decreased when combined with Letermovir.
Rucaparib The metabolism of Quinacrine can be decreased when combined with Rucaparib.
Fluticasone The metabolism of Quinacrine can be decreased when combined with Fluticasone.
Clofazimine The metabolism of Quinacrine can be decreased when combined with Clofazimine.
Pralsetinib The metabolism of Quinacrine can be decreased when combined with Pralsetinib.
Levoketoconazole The metabolism of Quinacrine can be decreased when combined with Levoketoconazole.
Acalabrutinib The metabolism of Quinacrine can be decreased when combined with Acalabrutinib.
Osilodrostat The metabolism of Quinacrine can be decreased when combined with Osilodrostat.
Modafinil The metabolism of Quinacrine can be increased when combined with Modafinil.
Icotinib The metabolism of Quinacrine can be increased when combined with Icotinib.
Budesonide The metabolism of Quinacrine can be increased when combined with Budesonide.
Dexamethasone acetate The metabolism of Quinacrine can be increased when combined with Dexamethasone acetate.
Beclomethasone dipropionate The metabolism of Quinacrine can be increased when combined with Beclomethasone dipropionate.
Thalidomide The metabolism of Quinacrine can be increased when combined with Thalidomide.
Armodafinil The metabolism of Quinacrine can be increased when combined with Armodafinil.
Oxcarbazepine The metabolism of Quinacrine can be increased when combined with Oxcarbazepine.
Triamcinolone The metabolism of Quinacrine can be increased when combined with Triamcinolone.
Cortisone acetate The metabolism of Quinacrine can be increased when combined with Cortisone acetate.
Paramethasone The metabolism of Quinacrine can be increased when combined with Paramethasone.
Fluprednidene The metabolism of Quinacrine can be increased when combined with Fluprednidene.
Meprednisone The metabolism of Quinacrine can be increased when combined with Meprednisone.
Dexamethasone isonicotinate The metabolism of Quinacrine can be increased when combined with Dexamethasone isonicotinate.
Cortivazol The metabolism of Quinacrine can be increased when combined with Cortivazol.
Prednylidene The metabolism of Quinacrine can be increased when combined with Prednylidene.
Cloprednol The metabolism of Quinacrine can be increased when combined with Cloprednol.
Mometasone furoate The metabolism of Quinacrine can be increased when combined with Mometasone furoate.

Target Protein

DNA
Phospholipase A2 PLA2G1B
85/88 kDa calcium-independent phospholipase A2 PLA2G6
Cytosolic phospholipase A2 PLA2G4A
Inactive phospholipase C-like protein 1 PLCL1

Referensi & Sumber

Artikel (PubMed)
  • PMID: 17072963
    Canete R, Escobedo AA, Gonzalez ME, Almirall P: Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children. World J Gastroenterol. 2006 Oct 21;12(39):6366-70.
  • PMID: 16623930
    Toubi E, Kessel A, Rosner I, Rozenbaum M, Paran D, Shoenfeld Y: The reduction of serum B-lymphocyte activating factor levels following quinacrine add-on therapy in systemic lupus erythematosus. Scand J Immunol. 2006 Apr;63(4):299-303.
  • PMID: 6109672
    Zipper J, Cole LP, Goldsmith A, Wheeler R, Rivera M: Quinacrine hydrochloride pellets: preliminary data on a nonsurgical method of female sterilization. Int J Gynaecol Obstet. 1980;18(4):275-9.
  • PMID: 1839351
    Bhatt RV: Camp laparoscopic sterilization deaths in Gujarat State, India, 1978-1980. Asia Oceania J Obstet Gynaecol. 1991 Dec;17(4):297-301.
  • PMID: 6136433
    Peterson HB, Lubell I, DeStefano F, Ory HW: The safety and efficacy of tubal sterilization: an international overview. Int J Gynaecol Obstet. 1983 Apr;21(2):139-44.

Contoh Produk & Brand

Produk: 0 • International brands: 1
International Brands
  • Atabrine

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul